华法林辅助治疗慢性阻塞性肺疾病患者的临床效果及对肺功能指标的影响

目的分析华法林辅助治疗慢性阻塞性肺疾病(COPD)患者的临床效果及对肺功能指标的影响。方法选取2017年11月至2018年12月我院呼吸内科收治的87例COPD患者作为研究对象,根据治疗方式的不同将其分成对照组(44例)和观察组(43例)。对照组采用常规对症治疗措施,观察组在此基础上应用华法林治疗。比较两组患者的临床疗效。结果观察组的治疗总有效率为88.37%(38/43),显著高于对照组的56.82%(25/44),差异有统计学意义(P<0.05);观察组的急性加重期发生率为11.63%(5/43),显著低于对照组的43.18%(19/44),差异有统计学意义(P<0.05)。治疗前,两组患者FEV1、FVC、FEV1/FVC、D-D、Fib水平及6 min步行距离比较,差异无统计学意义(P>0.05);治疗后,两组患者FEV1、FVC、FEV1/FVC、D-D、Fib水平及6 min步行距离均较治疗前明显改善,且观察组优于对照组(P<0.05)。结论华法林用于COPD患者中的疗效可靠,能明显改善患者肺功能指标、凝血指标水平,并增加6 min步行距离,值得推广应用。

Effect of warfarin in the adjuvant treatment of patients with chronic obstructive pulmonary disease and its influence on pulmonary function indicators

Objective To analyze the effect of warfarin in the adjuvant treatment of patients with chronic obstructive pulmonary disease(COPD) and its influence on pulmonary function indicators. Methods A total of 87 patients with COPD admitted in the respiratory department of our hospital from November 2017 to December 2018 were selected as the study objects. According to the different treatment methods, the patients were divided into control group(44 cases) and observation group(43 cases). The control group was treated with routine symptomatic treatment, while the observation group was treated with warfarin on this basis. The clinical efficacy were compared between the two groups. Results The total effective rate of treatment in the observation group was 88.37%(38/43), which was significantly higher than 56.82%(25/44) of the control group, and the difference was statistically significant(P<0.05);the incidence of acute exacerbation in the observation group was 11.63%(5/43), which was significantly lower than 43.18%(19/44) in the control group, and the difference was statistically significant(P<0.05). Before treatment, there were no significant differences in FEV1, FVC, FEV1/FVC, the levels of D-D and Fib, and 6-min walking distance of patients in the two groups(P>0.05);after treamtent, FEV1, FVC, FEV1/FVC,the levels of D-D and Fib, and 6-min walking distance of patients in the two groups improved significantly than before treatment, and those in the observation group were better than the control group(P<0.05). Conclusion Warfarin is reliable in the treatment of COPD patients, it can significantly improve the levels of indicators of pulmonary function and coagulation,and increase the 6-min walking distance, which is worth popularizing and applying.